Clinical Trial

Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions

Study acronym: LENNON
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 31, 2024 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
Anemia in patients with very low, low or intermediate risk myelodysplastic syndromes (MDS), that are non-transfusion dependent
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-05-17; most recent amendment 2024-01-30.
Status change: Not Yet Recruiting → Recruiting 2022-11-01
Trial Details
NCT Number NCT05384691
Lead Sponsor University of Leipzig
Collaborators: Celgene Corporation
Conditions Myelodysplastic Syndromes, Anemia
Enrollment 213 participants
Start Date 2022-09-27
Primary Completion 2026-07-31 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2024-01-31